IDYA IDEAYA Biosciences Inc.

8.77
-0.22  -2%
Previous Close 8.99
Open 8.73
Price To Book 2.01
Market Cap 178,903,527
Shares 20,399,490
Volume 150,684
Short Ratio
Av. Daily Volume 55,348
Stock charts supplied by TradingView

NewsSee all news

  1. IDEAYA Biosciences to Participate in Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020

    SOUTH SAN FRANCISCO, Calif., May 19, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for

  2. IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ/11 Tumors and Preclinical MAT2A Synthetic Lethality Program

    SOUTH SAN FRANCISCO, Calif., May 15, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for

  3. IDEAYA Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update

    SOUTH SAN FRANCISCO, Calif., May 12, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for

  4. IDEAYA Biosciences Announces Addition of Julie Patel as Vice President, Human Resources, Enhancing its Leadership Team

    SOUTH SAN FRANCISCO, Calif., April 21, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for

  5. IDEAYA Biosciences, Inc. Reports Fourth Quarter 2019 Financial Results and Provides Business Update

    SOUTH SAN FRANCISCO, Calif., March 24, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 interim data expected in 4Q 2020.
IDE196
Solid tumors
Phase 1 trial ongoing - one complete response confirmed October 31, 2019.
IDE196
Uveal Melanoma
Phase 1/2 trial to be initiated likely in 2020.
IDE196 and binimetinib
Solid Tumors

Latest News

  1. IDEAYA Biosciences to Participate in Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020

    SOUTH SAN FRANCISCO, Calif., May 19, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for

  2. IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ/11 Tumors and Preclinical MAT2A Synthetic Lethality Program

    SOUTH SAN FRANCISCO, Calif., May 15, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for

  3. IDEAYA Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update

    SOUTH SAN FRANCISCO, Calif., May 12, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for

  4. IDEAYA Biosciences Announces Addition of Julie Patel as Vice President, Human Resources, Enhancing its Leadership Team

    SOUTH SAN FRANCISCO, Calif., April 21, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for

  5. IDEAYA Biosciences, Inc. Reports Fourth Quarter 2019 Financial Results and Provides Business Update

    SOUTH SAN FRANCISCO, Calif., March 24, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for

  6. IDEAYA Biosciences Announces IDE196 Monotherapy Phase 2 Dose Selection and Clinical Program Update

    SOUTH SAN FRANCISCO, Calif., March 18, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to

  7. IDEAYA and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Binimetinib in Solid Tumors Harboring GNAQ or GNA11 Hotspot Mutations

    SOUTH SAN FRANCISCO, Calif., March 18, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to

  8. IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities

    SOUTH SAN FRANCISCO, Calif., March 11, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to

  9. IDEAYA Biosciences Announces Synthetic Lethality Research Highlights and Target Milestones for 2020

    SOUTH SAN FRANCISCO, Calif., Jan. 15, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to

  10. IDEAYA Biosciences and Boston Children's Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome - a Rare Disease Associated with Genetic Mutation of GNAQ

    SOUTH SAN FRANCISCO, Calif., Jan. 10, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics,

  11. IDEAYA Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020

    SOUTH SAN FRANCISCO, Calif., Jan. 6, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to

  12. IDEAYA Biosciences Appoints Wendy Yarno to its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Dec. 18, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to

  13. IDE196 Program Updates: Targeting Initiation of Potentially Registration-Enabling Phase 2 Single-Arm Monotherapy Trial in MUM and Introduction of Tablet Formulation in Q1 2020

    SOUTH SAN FRANCISCO, Calif., Dec. 9, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to

  14. Phase 1/2 Clinical Trial Data for IDE196 Presented at Society for Melanoma Research Congress

    SOUTH SAN FRANCISCO, Calif., Nov. 20, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to

  15. Phase 1/2 Clinical Trial Progress for IDE196 to be Presented at Society for Melanoma Research Congress

    SOUTH SAN FRANCISCO, Calif., Nov. 15, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to

  16. IDEAYA Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

    SOUTH SAN FRANCISCO, Calif., Nov. 13, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for

  17. IDEAYA Biosciences Announces Leadership Updates in Research Organization

    SOUTH SAN FRANCISCO, Calif., Nov. 5, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to

  18. IDEAYA Biosciences Reports End‑of‑Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single-Arm Trial Design for Potential Phase 2 Registration-Enabling Study in Metastatic Uveal Melanoma

    SOUTH SAN FRANCISCO, Calif., Oct. 31, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for